This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products including their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.
Peter Zhang, Chairman and CEO of Shanghai GenePharma, said: “This agreement with Alnylam reinforces our ability to become a leading global supplier of RNAi reagent products to the pharmaceutical and research community in China and worldwide. Access to the Kreutzer-Limmer patent estate allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace.”